source
- Scancell to list on Nasdaq after reverse merger with Neuphoria, funds $89M for melanoma immunotherapy trialScancell announced that it will become a publicly traded company on Nasdaq after completing an all‑stock reverse merger with Neophobia Therapeutics. The transaction gives Scancell a new ticker, SCL…
- FDA advisory panel to decide on compounding of synthetic peptides amid safety concernsThe FDA advisory committee is meeting to consider whether compounding pharmacies should be allowed to manufacture seven specific synthetic peptides. Use of these peptides has grown in the United St…